Improving the clinical impact of biomaterials in cancer immunotherapy

Oncotarget

Volumn 7, Issue 13, 2016, Pages 15421-15443

  Gammon, Joshua M ^a   Dold, Neil M ^a   Jewell, Christopher M ^a,b,c  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Biomaterials; Cancer immunotherapy; Cancer vaccine; Immune response; Immunity; Immunology and microbiology section; Nanotechnology; Translational medicine

Indexed keywords

ANTINEOPLASTIC AGENT; BIOMATERIAL; CD40 LIGAND MONOCLONAL ANTIBODY; CPG OLIGONUCLEOTIDE; FREUND ADJUVANT; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 12; IPILIMUMAB; NANOPARTICLE; NIVOLUMAB; OLIGONUCLEOTIDE; POLYMER; SIPULEUCEL T; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ARTICLE; ARTIFICIAL ANTIGEN PRESENTING CELL; BIOCOMPATIBILITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FREE THERAPY; CELL HOMING; CONTROLLED DRUG RELEASE; CYTOKINE RELEASE; DRUG DELIVERY DEVICE; HEALTH CARE DISPARITY; HUMAN; IMMUNE CHECKPOINT; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IMPLANTABLE BIODEGRADABLE DEVICE; LIPOSOMAL DELIVERY; MELANOMA; MEMORY T LYMPHOCYTE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR REPROGRAMMING; PARTICLE SIZE; PROSTATE CANCER; PROTEIN EXPRESSION; SELF ASSEMBLED LIPID PARTICLE; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; TOXICITY; TUMOR MICROENVIRONMENT; VIRUS LIKE AGENT; ANIMAL; DEVICES; NEOPLASM; PROCEDURES; TRENDS;

ANIMALS; BIOCOMPATIBLE MATERIALS; HUMANS; IMMUNOTHERAPY; NANOTECHNOLOGY; NEOPLASMS;

EID: 84971669218     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7304     Document Type: Article

References (162)

1. Weber JS, Yang JC, Atkins MB and Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015; 33:2092-U2154.
2. Motz GT and Coukos G. Deciphering and Reversing Tumor Immune Suppression. Immunity. 2013; 39:61-73.
3. Doroshow JH and Kummar S. Translational research in oncology-10 years of progress and future prospects. Nat Rev Clin Oncol. 2014; 11:649-662.
4. Rosenberg SA and Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348:62-68.
5. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014; 5:12472-12508. doi:10.18632/oncotarget.2998.
6. Kim J and Mooney DJ. In vivo modulation of dendritic cells by engineered materials: Towards new cancer vaccines. Nano Today. 2011; 6:466-477.
7. Sahdev P, Ochyl LJ and Moon JJ. Biomaterials for Nanoparticle Vaccine Delivery Systems. Pharm Res-Dordr. 2014; 31:2563-2582.
8. Bowen A and Casadevall A. Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research. P Natl Acad Sci USA. 2015; 112:11335-11340.
9. Singh A and Peppas NA. Hydrogels and Scaffolds for Immunomodulation. Adv Mater. 2014; 26:6530-6541.
10. Kim J, Li WA, Choi Y, Lewin SA, Verbeke CS, Dranoff G and Mooney DJ. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol. 2015; 33:64-U241.
11. Reategui E, Aceto N, Lim EJ, Sullivan JP, Jensen AE, Zeinali M, Martel JM, Aranyosi AJ, Li W, Castleberry S, Bardia A, Sequist LV, Haber DA, Maheswaran S, Hammond PT, Toner M, et al. Tunable Nanostructured Coating for the Capture and Selective Release of Viable Circulating Tumor Cells. Adv Mater. 2015; 27:1593-1599.
12. Domachuk P, Tsioris K, Omenetto FG and Kaplan DL. Bio-microfluidics: Biomaterials and Biomimetic Designs. Adv Mater. 2010; 22:249-260.
13. Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y and Santamaria P. Nanoparticle-Based Immunotherapy for Cancer. Acs Nano. 2015; 9:16-30.
14. Fang J, Nakamura H and Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliver Rev. 2011; 63:136-151.
15. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliver Rev. 2011; 63:161-169.
16. Andorko JI, Hess KL and Jewell CM. Harnessing Biomaterials to Engineer the Lymph Node Microenvironment for Immunity or Tolerance. Aaps J. 2015; 17:323-338.
17. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O'Hagan DT, Petrilli V, Tschopp J, O'Neill LAJ and Lavelle EC. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. P Natl Acad Sci USA. 2009; 106:870-875.
18. Andorko JI, Hess KL, Pineault KG and Jewell CM. Intrinsic immunogenicity of rapidly-degradable polymers evolves during degradation. Acta biomaterialia. 2016:In Press.
19. Hudalla GA, Sun T, Gasiorowski JZ, Han H, Tian YF, Chong AS and Collier JH. Gradated assembly of multiple proteins into supramolecular nanomaterials. Nature materials. 2014; 13:829-836.
20. Zhang P, Chiu YC, Tostanoski LH and Jewell CM. Polyelectrolyte Multilayers Assembled Entirely from Immune Signals on Gold Nanoparticle Templates Promote Antigen-Specific T Cell Response. Acs Nano. 2015; 9:6465-6477.
21. Y. C. Chiu, J.M. Gammon, J. I. Andorko, L. H. Tostanoski, and C. M. Jewell. Modular Vaccine Design Using Carrier-Free Capsules Assembled from Polyionic Immune Signals. ACS Biomater Sci Eng. 2015.
22. Venditto VJ and Szoka FC. Cancer nanomedicines: So many papers and so few drugs! Adv Drug Deliver Rev. 2013; 65:80-88.
23. Cheng ZL, Al Zaki A, Hui JZ, Muzykantov VR and Tsourkas A. Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities. Science. 2012; 338:903-910.
24. Juliano R. Nanomedicine: is the wave cresting? Nat Rev Drug Discov. 2013; 12:171-172.
25. Möhwald H and Weiss PS. Is Nano a Bubble? Acs Nano. 2015; 9:9427-9428.
26. Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol. 2008; 8:970-976.
27. Svenson S. What nanomedicine in the clinic right now really forms nanoparticles? Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2014; 6:125-135.
28. Carstens MG, Camps MGM, Henriksen-Lacey M, Franken K, Ottenhoff THM, Perrie Y, Bouwstra JA, Ossendorp F and Jiskoot W. Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine. 2011; 29:4761-4770.
29. Kwong B, Gai SA, Elkhader J, Wittrup KD and Irvine DJ. Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity. Cancer Research. 2013; 73:1547-1558.
30. Kwong B, Liu H and Irvine DJ. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials. 2011; 32:5134-5147.
31. Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP and Huang L. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Molecular therapy : the journal of the American Society of Gene Therapy. 2013; 21:1919-1929.
32. de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies AJ, Swartz MA and Hubbell JA. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013; 110:19902-19907.
33. Lemke CD, Geary SM, Joshi VB and Salem AK. Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations. Biomaterials. 2013; 34:2524-2529.
34. Hanson MC, Crespo MP, Abraham W, Moynihan KD, Szeto GL, Chen SH, Melo MB, Mueller S and Irvine DJ. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. Journal of Clinical Investigation. 2015; 125:2532-2546.
35. Radovic-Moreno AF, Chernyak N, Mader CC, Nallagatla S, Kang RS, Hao LL, Walker DA, Halo TL, Merkel TJ, Rische CH, Anantatmula S, Burkhart M, Mirkin CA and Gryaznov SM. Immunomodulatory spherical nucleic acids. P Natl Acad Sci USA. 2015; 112:3892-3897.
36. Hori Y, Stern PJ, Hynes RO and Irvine DJ. Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy. Biomaterials. 2009; 30:6757-6767.
37. Wen Y, Kolonich HR, Kruszewski KM, Giannoukakis N, Gawalt ES and Meng WS. Retaining Antibodies in Tumors with a Self-Assembling Injectable System. Molecular Pharmaceutics. 2013; 10:1035-1044.
38. Intra J, Zhang XQ, Williams RL, Zhu X, Sandler AD and Salem AK. Immunostimulatory sutures that treat local disease recurrence following primary tumor resection. Biomedical materials. 2011; 6:011001.
39. Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, Van Egeren DS, Park C and Irvine DJ. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014; 507:519-522.
40. Vo JL, Yang L, Kurtz SL, Smith SG, Koppolu BP, Ravindranathan S and Zaharoff DA. Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis. Oncoimmunology. 2014; 3:e968001-e968001.
41. June CH. Adoptive T cell therapy: Grand challenges and opportunities. J Immunother. 2007; 30:858-858.
42. Fadel TR, Sharp FA, Vudattu N, Ragheb R, Garyu J, Kim D, Hong E, Li N, Haller GL, Pfefferle LD, Justesen S, Herold KC and Fahmy TM. A carbon nanotube-polymer composite for T-cell therapy. Nature nanotechnology. 2014; 9:639-647.
43. Perica K, Bieler JG, Schutz C, Varela JC, Douglass J, Skora A, Chiu YL, Oelke M, Kinzler K, Zhou SB, Vogelstein B and Schneck JP. Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. Acs Nano. 2015; 9:6861-6871.
44. Wolfl M and Greenberg PD. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8(+) T cells. Nat Protoc. 2014; 9:950-966.
45. Stephan MT, Moon JJ, Um SH, Bershteyn A and Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nature medicine. 2010; 16:1035-1041.
46. Stephan MT, Stephan SB, Bak P, Chen J and Irvine DJ. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials. 2012; 33:5776-5787.
47. Zheng Y, Stephan MT, Gai SA, Abraham W, Shearer A and Irvine DJ. In vivo targeting of adoptively transferred T-cells with antibody-and cytokine-conjugated liposomes. Journal of controlled release : official journal of the Controlled Release Society. 2013; 172:426-435.
48. Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev. 2009; 228:342-359.
49. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12:252-264.
50. Sharma P and Allison JP. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell. 2015; 161:205-214.
51. Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL and Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2015; 33:97-101.
52. Pradhan P, Qin H, Leleux JA, Gwak D, Sakamaki I, Kwak LW and Roy K. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials. 2014; 35:5491-5504.
53. Singh A, Qin H, Fernandez I, Wei J, Lin J, Kwak LW and Roy K. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. Journal of controlled release : official journal of the Controlled Release Society. 2011; 155:184-192.
54. Smith SG, Koppolu BP, Ravindranathan S, Kurtz SL, Yang L, Katz MD and Zaharoff DA. Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer. Cancer immunology, immunotherapy : CII. 2015; 64:689-696.
55. Zaharoff DA, Hoffman BS, Hooper HB, Benjamin CJ, Jr., Khurana KK, Hance KW, Rogers CJ, Pinto PA, Schlom J and Greiner JW. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res. 2009; 69:6192-6199.
56. Crompton JG, Sukumar M and Restifo NP. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev. 2014; 257:264-276.
57. + T cells. The Journal of clinical investigation. 2005; 115:1616-1626.
58. Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM and Fahmy TM. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials. 2012; 33:4957-4964.
59. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP and Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460:108-U124.
60. Zeng R, Spolski R, Finkelstein SE, Oh SK, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA and Leonard WJ. Synergy of IL-21 and IL-15 in regulating CD8(+) T cell expansion and function. J Exp Med. 2005; 201:139-148.
61. Fofaria NM and Srivastava SK. Critical role of STAT3 in melanoma metastasis through anoikis resistance. Oncotarget. 2014; 5:7051-7064. doi:10.18632/oncotarget.2251.
62. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, Ott M, Ochs K, Lutz C, Liu XD, Anastasov N, Lehmann I, Hofer T, et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget. 2014; 5:1038-1051. doi:10.18632/oncotarget.1637.
63. Lee H, Pal SK, Reckamp K, Figlin RA and Yu H. STAT3: A Target to Enhance Antitumor Immune Response. Curr Top Microbiol. 2011; 344:41-59.
64. Alshamsan A, Hamdy S, Haddadi A, Samuel J, El-Kadi AOS, Uludağ H and Lavasanifar A. STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo. Translational oncology. 2011; 4:178-188.
65. Alshamsan A, Haddadi A, Hamdy S, Samuel J, El-Kadi AOS, Uludağ H and Lavasanifar A. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Molecular Pharmaceutics. 2010; 7:1643-1654.
66. Molavi O, Mahmud A, Hamdy S, Hung RW, Lai R, Samuel J and Lavasanifar A. Development of a poly(D,L-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: Implication for cancer immunotherapy. Molecular Pharmaceutics. 2010; 7:364-374.
67. Jewell CM, Lopez SCB and Irvine DJ. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. P Natl Acad Sci USA. 2011; 108:15745-15750.
68. Andorko JI, Tostanoski LH, Solano E, Mukhamedova M and Jewell CM. Intra-lymph node injection of biodegradable polymer particles. Journal of visualized experiments : JoVE. 2014; e50984.
69. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MYK, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML and Gajewski TF. STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors. Immunity. 2014; 41:830-842.
70. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, Garcia-Sastre A, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011; 470:543-U136.
71. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM and Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015; 33:1889-U1848.
72. Thara E, Dorff TB, Pinski JK and Quinn DI. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011; 69:296-303.
73. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA and Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24:3089-3094.
74. Mulders PF, De Santis M, Powles T and Fizazi K. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immun. 2015; 64:655-663.
75. Palucka K and Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12:265-277.
76. Bencherif SA, Warren Sands R, Ali OA, Li WA, Lewin SA, Braschler TM, Shih TY, Verbeke CS, Bhatta D, Dranoff G and Mooney DJ. Injectable cryogel-based whole-cell cancer vaccines. Nature communications. 2015; 6:7556.
77. Ali OA, Doherty E, Mooney DJ and Emerich D. Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines. Biomatter. 2011; 1:66-75.
78. Ali OA, Huebsch N, Cao L, Dranoff G and Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nature materials. 2009; 8:151-158.
79. Ali OA, Tayalia P, Shvartsman D, Lewin S and Mooney DJ. Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs. Advanced functional materials. 2013; 23:4621-4628.
80. Ali OA, Verbeke C, Johnson C, Sands RW, Lewin SA, White D, Doherty E, Dranoff G and Mooney DJ. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res. 2014; 74:1670-1681.
81. Joshi VB, Geary SM, Carrillo-Conde BR, Narasimhan B and Salem AK. Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles. Acta biomaterialia. 2013; 9:5583-5589.
82. Vasievich EA, Chen W and Huang L. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer immunology, immunotherapy : CII. 2011; 60:629-638.
83. Vasievich EA, Ramishetti S, Zhang Y and Huang L. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol Pharm. 2012; 9:261-268.
84. Black M, Trent A, Kostenko Y, Lee JS, Olive C and Tirrell M. Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo. Adv Mater. 2012; 24:3845-3849.
85. Campbell DF, Saenz R, Bharati IS, Seible D, Zhang L, Esener S, Messmer B, Larsson M and Messmer D. Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles. Breast cancer research : BCR. 2015; 17:48.
86. Julier Z, Martino MM, de Titta A, Jeanbart L and Hubbell JA. The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine. Scientific reports. 2015; 5:8569.
87. Liu TY, Hussein WM, Giddam AK, Jia Z, Reiman JM, Zaman M, McMillan NA, Good MF, Monteiro MJ, Toth I and Skwarczynski M. Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine. Journal of medicinal chemistry. 2015; 58:888-896.
88. Liu TY, Hussein WM, Jia Z, Ziora ZM, McMillan NA, Monteiro MJ, Toth I and Skwarczynski M. Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. Biomacromolecules. 2013; 14:2798-2806.
89. Phua KK, Boczkowski D, Dannull J, Pruitt S, Leong KW and Nair SK. Whole blood cells loaded with messenger RNA as an anti-tumor vaccine. Advanced healthcare materials. 2014; 3:837-842.
90. Liu Y, Xiao L, Joo KI, Hu B, Fang J and Wang P. In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules. 2014; 15:3836-3845.
91. Phua KKL, Staats HF, Nair SK and Leong KW. Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Journal of Controlled Release. 2015; 213:E66-E67.
92. Irvine DJ, Swartz MA and Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nature materials. 2013; 12:978-990.
93. Moon JJ, Suh H, Bershteyn A, Stephan MT, Liu HP, Huang B, Sohail M, Luo S, Um SH, Khant H, Goodwin JT, Ramos J, Chiu W and Irvine DJ. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nature materials. 2011; 10:243-251.
94. Kovacsovicsbankowski M and Rock KL. A Phagosome-to-Cytosol Pathway for Exogenous Antigens Presented on Mhc Class-I Molecules. Science. 1995; 267:243-246.
95. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM and Hanlon DJ. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006; 117:78-88.
96. Hirosue S, Kourtis IC, van der Vlies AJ, Hubbell JA and Swartz MA. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine. 2010; 28:7897-7906.
97. Scott EA, Stano A, Gillard M, Maio-Liu AC, Swartz MA and Hubbell JA. Dendritic cell activation and T cell priming with adjuvant-and antigen-loaded oxidation-sensitive polymersomes. Biomaterials. 2012; 33:6211-6219.
98. Keller S, Wilson JT, Patilea GI, Kern HB, Convertine AJ and Stayton PS. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. Journal of Controlled Release. 2014; 191:24-33.
99. Wilson JT, Postma A, Keller S, Convertine AJ, Moad G, Rizzardo E, Meagher L, Chiefari J and Stayton PS. Enhancement of MHC-I Antigen Presentation via Architectural Control of pH-Responsive, Endosomolytic Polymer Nanoparticles. Aaps J. 2015; 17:358-369.
100. Foster S, Duvall CL, Crownover EF, Hoffman AS and Stayton PS. Intracellular Delivery of a Protein Antigen with an Endosomal-Releasing Polymer Enhances CD8 T-Cell Production and Prophylactic Vaccine Efficacy. Bioconjugate Chem. 2010; 21:2205-2212.
101. Wilson JT, Keller S, Manganiello MJ, Cheng C, Lee CC, Opara C, Convertine A and Stayton PS. pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory Oligonucleotides. Acs Nano. 2013; 7:3912-3925.
102. Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Lowik C, Oostendorp J, van der Burg SH and Ossendorp F. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2015; 40:88-97.
103. Zeng Q, Jiang H, Wang T, Zhang Z, Gong T and Sun X. Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses. Journal of controlled release : official journal of the Controlled Release Society. 2015; 200:1-12.
104. Seong SY and Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004; 4:469-478.
105. Perica K, De Leon Medero A, Durai M, Chiu YL, Bieler JG, Sibener L, Niemoller M, Assenmacher M, Richter A, Edidin M, Oelke M and Schneck J. Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine : nanotechnology, biology, and medicine. 2014; 10:119-129.
106. Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP and Bronte V. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res. 2009; 69:9376-9384.
107. de Gruijl TD, van den Eertwegh AJM, Pinedo HM and Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunol Immun. 2008; 57:1569-1577.
108. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC. Vaccination with Irradiated Tumor-Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Antitumor Immunity. P Natl Acad Sci USA. 1993; 90:3539-3543.
109. Ali OA, Emerich D, Dranoff G and Mooney DJ. In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice. Sci Transl Med. 2009; 1.
110. Bencherif SA, Sands RW, Bhatta D, Arany P, Verbeke CS, Edwards DA and Mooney DJ. Injectable preformed scaffolds with shape-memory properties. Proc Natl Acad Sci U S A. 2012; 109:19590-19595.
111. Arlen PM, Mohebtash M, Madan RA and Gulley JL. Promising novel immunotherapies and combinations for prostate cancer. Future Oncol. 2009; 5:187-196.
112. Bartholomew RM. GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US). 2015 (Accessed 12/14/2015):Available using NLM Identifier NCT02243371.
113. Zheng L. Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US). 2015 (Accessed 12/14/2015):Available using NLM Identifier NCT02451982.
114. Fong S. A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US). 2015 (Accessed 12/14/2015 ):Available using NLM Identifier NCT01804465.
115. Wrzesinski SH, Wan YSY and Flavell RA. Transforming growth factor-beta and the immune response: Implications for anticancer therapy. Clin Cancer Res. 2007; 13:5262-5270.
116. Holmgaard RB, Zamarin D, Li YY, Gasmi B, Munn DH, Allison JP, Merghoub T and Wolchok JD. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13:412-424.
117. Xu ZH, Wang YH, Zhang L and Huang L. Nanoparticle-Delivered Transforming Growth Factor-beta siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment. Acs Nano. 2014; 8:3636-3645.
118. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015; 373:23-34.
119. Fox CB, Sivananthan SJ, Duthie MS, Vergara J, Guderian JA, Moon E, Coblentz D, Reed SG and Carter D. A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7. Journal of nanobiotechnology. 2014; 12:17-17.
120. + T-cell responses in melanoma patients. European journal of immunology. 2012; 42:3049-3061.
121. Thomas SN, Vokali E, Lund AW, Hubbell JA and Swartz MA. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials. 2014; 35:814-824.
122. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C and Hellman J. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol. 2007; 178:1164-1171.
123. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM and Berzofsky JA. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. The Journal of clinical investigation. 2010; 120:607-616.
124. Timmermans K, Plantinga TS, Kox M, Vaneker M, Scheffer GJ, Adema GJ, Joosten LAB and Netea MG. Blueprints of Signaling Interactions between Pattern Recognition Receptors: Implications for the Design of Vaccine Adjuvants. Clin Vaccine Immunol. 2013; 20:427-432.
125. Tom JK, Mancini RJ and Esser-Kahn AP. Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation. Chem Commun. 2013; 49:9618-9620.
126. Delamarre L, Mellman I and Yadav M. Cancer immunotherapy. Neo approaches to cancer vaccines. Science. 2015; 348:760-761.
127. McCarthy DP, Hunter ZN, Chackerian B, Shea LD and Miller SD. Targeted immunomodulation using antigen-conjugated nanoparticles. Wires Nanomed Nanobi. 2014; 6:298-315.
128. Rosenthal JA, Chen LX, Baker JL, Putnam D and DeLisa MP. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale. Curr Opin Biotech. 2014; 28:51-58.
129. Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, et al. Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients. J Immunother. 2010; 33:848-858.
130. Makkouk A, Joshi VB, Wongrakpanich A, Lemke CD, Gross BP, Salem AK and Weiner GJ. Biodegradable Microparticles Loaded with Doxorubicin and CpG ODN for In Situ Immunization Against Cancer. The AAPS Journal. 2014; 17:184-193.
131. Roy A, Singh MS, Upadhyay P and Bhaskar S. Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. International Journal of Pharmaceutics. 2013; 445:171-180.
132. Chu KF and Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014; 14:199-208.
133. Lumniczky K and Safrany G. The impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences. Cancer Lett. 2015; 356:114-125.
134. Formenti SC and Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009; 10:718-726.
135. Marrache S, Choi JH, Tundup S, Zaver D, Harn Da and Dhar S. Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer. Integrative Biology. 2012:215-223.
136. Kourtis IC, Hirosue S, de Titta A, Kontos S, Stegmann T, Hubbell JA and Swartz MA. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PloS one. 2013; 8:e61646.
137. Azarin SM, Yi J, Gower RM, Aguado BA, Sullivan ME, Goodman AG, Jiang EJ, Rao SS, Ren Y, Tucker SL, Backman V, Jeruss JS and Shea LD. In vivo capture and label-free detection of early metastatic cells. Nature communications. 2015; 6:8094.
138. Huang BN, Abraham WD, Zheng YR, Lopez SCB, Luo SS and Irvine DJ. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci Transl Med. 2015; 7.
139. Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK and Levy R. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood. 2015; 125:2079-2086.
140. Liu H, Kwong B and Irvine DJ. Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy. Angewandte Chemie. 2011; 50:7052-7055.
141. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L and Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17:2105-2116.
142. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM and Rosenberg SA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008; 14:5610-5618.
143. Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, Jay SM, Demento SL, Agawu A, Licona Limon P, Ferrandino AF, Gonzalez D, Habermann A, Flavell RA and Fahmy TM. Combination delivery of TGF-beta inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nature materials. 2012; 11:895-905.
144. Burrell RA, McGranahan N, Bartek J and Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501:338-345.
145. Meacham CE and Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501:328-337.
146. Stevanovic S. Identification of tumour-associated T-CELL epitopes for vaccine development. Nat Rev Cancer. 2002; 2:514-520.
147. Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S and Slingluff CL. Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma. The Journal of Immunology. 2005; 174:6863-6871.
148. Schumacher TN and Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348:69-74.
149. Neller MA, Lopez JA and Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol. 2008; 20:286-295.
150. Schreiber RD, Old LJ and Smyth MJ. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. Science. 2011; 331:1565-1570.
151. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR and Delamarre L. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014; 515:572.
152. Gubin MM, Zhang XL, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SSK, Korman AJ, Allison JP, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515:577.
153. Castle JC, Kreiter S, Diekmann J, Lower M, Van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn AN, Britten CM, Huber C, Tuereci O and Sahin U. Exploiting the Mutanome for Tumor Vaccination. Cancer Research. 2012; 72:1081-1091.
154. Prasad S, Cody V, Saucier-Sawyer JK, Saltzman WM, Sasaki CT, Edelson RL, Birchall MA and Hanlon DJ. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine : nanotechnology, biology, and medicine. 2011; 7:1-10.
155. Gross BP, Wongrakpanich A, Francis MB, Salem AK and Norian LA. A Therapeutic Microparticle-Based Tumor Lysate Vaccine Reduces Spontaneous Metastases in Murine Breast Cancer. Aaps J. 2014; 16:1194-1203.
156. Damo M, Wilson DS, Simeoni E and Hubbell JA. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Scientific reports. 2015; 5:17622.
157. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014; 32:479-U202.
158. Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, Engstrom A, Zhu H, Sundaresan TK, Miyamoto DT, Luo X, Bardia A, Wittner BS, Ramaswamy S, Shioda T, Ting DT, et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015; 12:685.
159. Park GS, Kwon H, Kwak DW, Park SY, Kim M, Lee JH, Han H, Heo S, Li XS, Lee JH, Kim YH, Lee JG, Yang W, Cho HY, Kim SK and Kim K. Full Surface Embedding of Gold Clusters on Silicon Nanowires for Efficient Capture and Photothermal Therapy of Circulating Tumor Cells (vol 12, pg 1638, 2012). Nano Lett. 2012; 12:2176-2176.
160. Fierer JO, Veggiani G and Howarth M. SpyLigase peptide-peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture. P Natl Acad Sci USA. 2014; 111:E1176-E1181.
161. Li P, Mao ZM, Peng ZL, Zhou LL, Chen YC, Huang PH, Truica CI, Drabick JJ, El-Deiry WS, Dao M, Suresh S and Huang TJ. Acoustic separation of circulating tumor cells. P Natl Acad Sci USA. 2015; 112:4970-4975.
162. Halo TL, McMahon KM, Angeloni NL, Xu YL, Wang W, Chinen AB, Malin D, Strekalova E, Cryns VL, Cheng CH, Mirkin CA and Thaxton CS. NanoFlares for the detection, isolation, and culture of live tumor cells from human blood. P Natl Acad Sci USA. 2014; 111:17104-17109.